• Revenue of A$5.99 billion, down from A$6.58 billion in the prior period
• EBITDA of A$275.8 million, down from A$303.1 million in the prior period
• Profit for the period of A$111.7 million, down from A$137.3 million in the prior period

Ebos Group Ltd has reported its interim results for the six months ended 31 December 2024. The company's revenue decreased to A$5.99 billion, down from A$6.58 billion in the prior corresponding period. Earnings before depreciation, amortisation, net finance costs and tax expense (EBITDA) declined to A$275.8 million, compared to A$303.1 million in the prior period. Profit for the period was A$111.7 million, down from A$137.3 million in the prior corresponding period. The company has declared an interim dividend of 57.0 cents per share, in line with the prior period. Ebos Group's financial position remains strong, with equity attributable to owners of the company of A$2.48 billion as at 31 December 2024. The company continues to focus on its strategic initiatives to drive growth and improve operational efficiency across its healthcare and animal care businesses.